Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer

Lu,Hong-Yang; Su,Dan; Pan,Xiao-Dan; Jiang,Hong; Ma,Sheng-Lin

doi:10.3892/ol.2011.502

Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer

Authors:
- Hong-Yang Lu
- Dan Su
- Xiao-Dan Pan
- Hong Jiang
- Sheng-Lin Ma
View Affiliations

Affiliations: Zhejiang Key Laboratory of the Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, P.R. China, Department of Oncology, Hangzhou First People's Hospital, Hangzhou 310006, P.R. China
Published online on: November 30, 2011 https://doi.org/10.3892/ol.2011.502
Pages: 415-420

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Individual therapy based on various pathohistological types and biological characteristics may be the practical trend of advanced non-small cell lung cancer (NSCLC) treatment. To provide a molecular criterion for drug selection, we investigated the incidence of somatic mutation and mRNA expression levels of common genes relevant to treatment response in a population with locally advanced NSCLC. Mutant-enriched and branched DNA-liquidchip technology (bDNA‑LCT) were used to detect the somatic mutations in the epidermal growth factor receptor (EGFR), KRAS, BRAF and phosphatidylinositol‑3-kinase catalytic α (PIK3CA) genes, and mRNA levels of EGFR, ERCC1, class III β-tubulin (TUBB3) and TYMS, separately, in paraffin tissue blocks from 30 patients with stage IIIA NSCLC. Our current findings revealed that 6, 4 and 2 out of 30 samples were found with mutations in exons 19, 21 and 20 of the EGFR gene, respectively. The mutation incidence of exons 19 and 21 had a positive correlation with EGFR mRNA expression. Mutations in exons 12 and 13 of the K-ras gene were found in 2 out of 30, and 1 out of 30 samples, separately. Three out of 30 samples were found with mutations in codon 542 of the PIK3CA gene. No mutations were found in the BRAF gene. The expression levels of ERCC1 and TUBB3 mRNAs were higher in patients with adenocarcinoma than those in patients with squamous cell carcinoma. The expression of TYMS mRNA in patients with adenocarcinoma was lower than that in patients with squamous cell carcinoma. In conclusion, mutations and mRNA expression of these commonly studied genes provides a basis for the selection of suitable molecular markers for individual treatment in a population with locally advanced NSCLC.

View Figures

View References

1	O'Rourke N and Macbeth F: Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence. Clin Oncol. 22:347–355. 2010. View Article : Google Scholar
2	Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 28:744–752. 2010. View Article : Google Scholar : PubMed/NCBI
3	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
4	Vilmar A, Santoni-Rugiu E and Sørensen JB: ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer. 46:1554–1562. 2010. View Article : Google Scholar : PubMed/NCBI
5	Sève P, Mackey J, Isaac S, et al: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 4:2001–2007. 2005.
6	Joerger M, Omlin A, Cerny T, et al: The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Target. 11:37–47. 2010. View Article : Google Scholar : PubMed/NCBI
7	Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
8	Wu YL, Zhong WZ, Li LY, et al: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007. View Article : Google Scholar
9	Dahabreh IJ, Linardou H, Siannis F, et al: Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 16:291–303. 2010. View Article : Google Scholar : PubMed/NCBI
10	Martinez E, Martinez M, Viñolas N, et al: Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: a prospective randomized phase II study. J Clin Oncol. 26(Suppl): 75632008.
11	Slebos RJ, Kibbelaar RE, Dalesio ON, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 323:561–565. 1990. View Article : Google Scholar : PubMed/NCBI
12	Mascaux C, Iannino N, Martin B, et al: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 92:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
13	Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 352:2589–2597. 2005. View Article : Google Scholar
14	Gautschi O, Huegli B, Ziegler A, et al: Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 254:265–273. 2007. View Article : Google Scholar : PubMed/NCBI
15	Jackman DM, Miller VA, Cioffredi LA, et al: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 15:5267–5273. 2009. View Article : Google Scholar
16	Naoki K, Chen TH, Richards WG, et al: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 62:7001–7003. 2002.PubMed/NCBI
17	Okudela K, Suzuki M, Kageyama S, et al: PIK3CA mutation and amplification in human lung cancer. Pathol Int. 57:664–671. 2007. View Article : Google Scholar : PubMed/NCBI
18	Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
19	Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar : PubMed/NCBI
20	Govindan R, Bogart J, Wang X, et al: Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol. 27(Suppl): 75052009.PubMed/NCBI
21	Shenglin M, Yaping X, Yongling J, et al: Concomitant pemetrexed/carboplatin chemotherapy and 3D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy for locally advanced non-small cell lung cancer: preliminary results of a phase II study. J Clin Oncol. 28(Suppl): 70922010.